Other substances

Bis3

An anti-RBD (SARS-CoV-2 Spike) fusion antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Bis3 is an antibody fusion construct combining a neutralizing (variable heavy domain) and non-neutralizing (Fab) antibody domains recognizing different epitopes on RBD (SARS-CoV-2 Spike protein), assembled on a single IgG scaffold. The construct showed improved neutralization potency in vitro (Lim et al., 2021).

Synonyms

VH A01/Fab D01

 

Supporting references

Link Tested on Impact factor Notes Publication date
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
Spike protein Biophysical assay In vitro Antibody 		in vitro binding assay; in vitro biophysical assay; HEK-ACE2 cells; Vero E6 cells; (HIV-1) SARS-CoV-2 Spike pseudovirus; SARS-CoV-2 isolate USA-WA1/2020 4.63

The fusion antibody displayed high affinity to SARS-CoV-2 S ectodomain and neutralized live SARS-CoV-2 virus and SARS-CoV-2 Spike pseudotyped virus with IC50s of ca. 1 nM and 0.128 nM, respectively, in vitro.

 Mar/05/2021
Export (.csv)